Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion.
Haematologica • Vol. 106, Issue 9 • 2021
The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.
Immunology • Vol. 160, Issue 1 • 2020
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hematological oncology • Vol. 37, Issue 4 • 2019
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Journal of medicinal chemistry • Vol. 62, Issue 17 • 2019